Full Title: Oxford Precision Oncology for Sarcoma (Ox-POS): a prospective, longitudinal, observational study with integration of NAVIFY® pathway decision support

Status: Active, Recruiting

Age Range: 18+ years


Oxford University Hospitals NHS Trust

Registry Number: ISRCTN16717882

Patients with sarcoma face challenges in receiving the correct diagnosis and frequently endure major surgery and toxic chemotherapy treatment. Advances in technology have the potential to improve the accuracy of diagnosis and to allow for more targeted cancer treatments.

This study is aiming to determine whether the integration of new technologies to gather more detailed information on an individual’s cancer can result in measurable improvements in care for patients with sarcoma.

These technologies include new sequencing tests that provide information on the genetic make-up of an individual cancer, as well as new analysis techniques applied to body scans and more in-depth, integrated analysis of all of this data collected.

Patients with a diagnosis of high-grade (grade 1 / 2) sarcoma who are receiving care under the Oxford sarcoma multi-disciplinary team will be invited to participate.

All participants will still receive the usual standard or care throughout their time on the study. They will be asked to provide an additional blood test and to consent to the use of excess material from their tumour biopsy or surgery for further genetic testing. They will also be asked to complete questionnaires relating to their psychological well-being and quality of life.

As part of their routine care, patients will have undergone a body scan. Following routine analysis of this scan and provision of the information to the patient’s doctor, the scan data may then be made available to the study team for more advanced, in-depth analysis. Some participants may be asked to undergo an additional study-specific scan (if their sarcoma later progresses).

A small number of participants may be asked to undergo an additional study-specific biopsy to provide a sample for additional gene testing. However, this procedure is entirely voluntary and opting out of this additional test will not affect participation in the rest of the study.

All of the data collected will be pseudo-anonymised (meaning directly identifying details will be removed) and will comply with data protection legislation.

The in-depth analyses performed in this study may elicit additional findings which benefit the care of each individual participant, as well the care of sarcoma patients overall. How clinicians use the new, in-depth data to inform decisions made as part of patients’ multi-disciplinary team will also be assessed.

If you would like any more information on clinical trials in general, please contact us at Bone Cancer Research Trust. For more information on this study and to understand if you are eligible, please talk to your clinical team.

Donate now (This link opens in a new window) More about All cancer types